Accolade, Inc. (NASDAQ:ACCD) Given Consensus Recommendation of “Hold” by Analysts

Accolade, Inc. (NASDAQ:ACCD) has received a consensus rating of “Hold” from the thirteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Twelve investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $6.51.

A number of analysts have issued reports on the stock. Stephens reiterated an “equal weight” rating and issued a $7.03 target price on shares of Accolade in a research note on Wednesday, February 12th. Raymond James reiterated a “market perform” rating on shares of Accolade in a research note on Thursday, January 9th. Leerink Partners reiterated a “market perform” rating on shares of Accolade in a research note on Wednesday, January 8th. Morgan Stanley reduced their target price on shares of Accolade from $6.00 to $5.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $7.03 target price (down from $8.00) on shares of Accolade in a research note on Thursday, January 9th.

Accolade Stock Performance

Shares of ACCD opened at $6.97 on Thursday. The company’s 50 day moving average price is $6.28 and its 200 day moving average price is $4.63. Accolade has a 52 week low of $3.08 and a 52 week high of $10.68. The company has a market capitalization of $571.49 million, a PE ratio of -3.10 and a beta of 2.18. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings data on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. Research analysts expect that Accolade will post -1.2 EPS for the current fiscal year.

Institutional Trading of Accolade

A number of institutional investors and hedge funds have recently modified their holdings of ACCD. Mission Creek Capital Partners Inc. acquired a new position in Accolade during the 3rd quarter valued at $38,000. Pallas Capital Advisors LLC acquired a new position in Accolade during the 4th quarter valued at $38,000. Laird Norton Wetherby Trust Company LLC acquired a new position in Accolade during the 4th quarter valued at $38,000. Boothbay Fund Management LLC acquired a new position in Accolade during the 4th quarter valued at $43,000. Finally, Wolverine Trading LLC acquired a new position in Accolade during the 3rd quarter valued at $51,000. 84.99% of the stock is currently owned by institutional investors and hedge funds.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.